Gynecologic Cancer

Cervical/vaginal

- **10113**: A Phase I Study of the Wee 1 Kinase (Wee 1) Inhibitor AZD1775 in Combination with Radiotherapy and Cisplatin in Cervical, Upper Vaginal and Uterine Cancers
- **9892**: Phase I Dose-Escalation Bioavailability Study of Oral Triapine in Combination with Concurrent Chemoradiation for Locally Advanced Cervical Cancer (LACC) and Vaginal Cancer
- **10104**: A Randomized Phase 2 Study of Cabozantinib in Combination with Nivolumab in Advanced, Recurrent Metastatic Endometrial Cancer (Exploratory cohort eligibility: Endometrial carcinosarcoma only)

Endometrial

- **10017**: A Randomized Phase 2 Trial of Atezolizumab (MPDL3280A), SGI-110 and CDX-1401 Vaccine in Recurrent Ovarian Cancer
- **9948**: Phase 1 Dose Escalation and Expansion Cohort of Carboplatin and Gemcitabine with or without M6620 (VX-970) in First or Second Recurrence Platinum-Sensitive Epithelial Ovarian, Peritoneal, and Fallopian Tube Cancer
- **10140**: A Randomized Phase 2 Study of Bevacizumab and Either Weekly Anetumab Ravtansine or Weekly Paclitaxel in Platinum-Resistant or Platinum Refractory Ovarian Cancer

Ovarian

- **9676**: A Phase 1 Trial of MK-3475 Plus Ziv-Aflibercept in Patients with Advanced Solid Tumors (Expansion phase, Pt. 1 includes melanoma, renal cell, ovarian, and colorectal cancer)
- **10324**: A Phase 1b Dose Escalation Study of Pegylated Liposomal Doxorubicin (PLD) with M3814 in Ovarian Cancer with Planned Expansion in Low Grade Serous Ovarian Cancer (LGSOC) (Escalation phase: ovarian, fallopian tube, or peritoneal; Expansion phase: serous ovarian cancer)
- **10031**: A Phase 1 Study of PARP Inhibitor Olaparib and HSP90 Inhibitor AT13387 for Treatment of Advanced Solid Tumors with Expansion in Patients with Recurrent Epithelial Ovarian, Fallopian Tube, Peritoneal Cancer or Recurrent Triple-Negative Breast Cancer (Dose escalation: solid tumors)
- **10250**: A Phase II Study of the PARP Inhibitor Olaparib in Combination with the DNA Damaging Agent Temozolomide for the Treatment of Advanced Uterine Leiomyosarcoma